Italy's Chiesi buys Zymenex for rare genetic disease work; Analysts forecast blockbuster sale for Roche schizophrenia drug;

@FierceBiotech: Syndax snags $26.6M round for Phase III breast cancer study. More | Follow @FierceBiotech

@JohnCFierce: Patient advocacy or Amgen's blockbuster protection act? Biosimilars bills advance. Report | Follow @JohnCFierce

> Italy's Chiesi Group is acquiring Zymenex, a UK group focused on developing new therapies for rare genetic diseases. Release

> Decision Resources says that Roche/Chugai's schizophrenia drug bitopertin should go on to earn $1.5 billion after a launch in 2016. Story

Medical Device News

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter tomorrow. Sign up here | Follow @FierceMedDev

@DamianFierce: Covidien has opened the doors of a new $21M South Korean R&D shop. More | Follow @DamianFierce

@MarkHFierce: Edwards, fresh from a patent lawsuit victory, is heralding a German injunction on Medtronic CoreValve sales. Story | Follow @MarkHFierce

@MichaelGFierce: Ceptaris nets first-ever FDA approval for topical lymphoma chemo gel. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien cuts ribbon on $21M Korean R&D shop. Report

> New sleep apnea treatment devices emerge. Story

> LDR files for $69M IPO following FDA approval. Article

> Volcano buying Medtronic's imaging catheter. News

> Vestagen pulls in $8.25 million for high-tech medical scrub uniforms. Item

Pharma News

@FiercePharma: Sudden CFO departure at Actelion, just as Swiss drug maker wraps up Ceptaris buyout. More | Follow @FiercePharma

@EricPFierce: Swiss CMO Siefried building a manufacturing plant in China. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Low vaccination rate at megachurch linked to measles outbreak. Story Follow @CarlyHFierce

> China arrests British couple for trafficking in private information. News

> Bayer's Nexavar in FDA fast lane for thyroid cancer use. Report

> Akorn buys rival Hi-Tech for $640M. Article

> Lonza will cut 200 at Massachusetts plant by end of year. Story

Biotech Research News

@EmilyMFierce: Omega-3 alleviates ADHD symptoms in rats. More | Follow @EmilyMFierce

> High copper levels implicated in Alzheimer's disease. Story

> Single injection could provide new treatment for melanoma. Article

> New target to battle Parkinson's discovered. News

> Gene therapy in mice improves Rett syndrome. More

> Sodium 'switch' could provide target to treat brain disorders. Item

Pharma Manufacturing News

> Akorn buys Hi-Tech for $640M to tap manufacturing expertise. Report

> Amarin asks FDA to approve Novasep as Vascepa partner. Story

> Lonza starting job cuts at troubled U.S. biologics plant. Article

> Ontario helps Pillar5 expand plant. Item

> Another Fresenius plant in FDA crosshairs. More

And Finally… Researchers at the Salk Institute in La Jolla, CA, say that a molecule that blocks light sensors in the eye could be effective in treating migraines. Release

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.